<DOC>
	<DOCNO>NCT01508884</DOCNO>
	<brief_summary>Despite WHO International Health Regulations Emergency Committee declare end 2009 H1N1 pandemic globally , emergence novel 2009 H1N1 virus March 2009 affect 214 country least 18000 death [ 1 ] . Patients chronic underlying illness extreme age risk develop severe disease complication [ 2-3 ] . Resistance oseltamivir also report [ 4 ] . Therefore , vaccination 2010/2011 trivalent influenza vaccine ( TIV ) 2009 H1N1-like virus incorporate best protection influenza infection , especially among risk population . Recent study dose spar seasonal influenza vaccine deliver via novel intradermal microneedle demonstrate good immunogenic response similar full-dose intramuscular vaccination [ 6 ] . Poor immunogenicity H1N1 2009 component trivalent influenza report [ 7 ] . Study also suggest combined intradermal vaccination local stimulation dermal antigen present cell apply imiquimod cream ( Aldara ) injection site , activate antigen presenting cell ( APC ) toll-like receptor 7 ( TLR7 ) may produce good immunogenicity [ 8 ] . Imiquimod cream currently register treatment wart basal cell carcinoma . Scientific evidence demonstrate treatment imiquimod , antigen process presented cell adaptive immune system lead clearance virus subsequent clearance lesion [ 9 ] . In addition functional maturation , imiquimod induces migration dendritic cell dermis drain lymph node [ 10,11 ] . Subcutaneous administration imiquimod vaccine adjuvant simultaneously antigen interest , show induce enhance response towards administer antigen [ 12 ] . We therefore perform prospective , double blind , randomize control study compare safety immunogenicity intradermal 2011/2012 TIV immunization pretreatment imiquimod cream conventional full dose intramuscular 2011/2012 TIV immunization pretreatment aqueous cream control .</brief_summary>
	<brief_title>Intradermal Trivalent Influenza Vaccine With Imiquimod</brief_title>
	<detailed_description>References 1 . World Health Organization . Influenza A ( H1N1 ) - update 95 [ cite 2010 April 10 ] . Available http : //www.who.int/csr/don/2009_12_30/en/index.html 2 . Echevarria-Zuno S , Mejia-Arangure JM , Mar-Obeso AJ , et al . Infection death influenza A H1N1 virus Mexico : retrospective analysis . Lancet 2009 ; 374 : 2072-9 . 3 . Louie JK , Acosta M , Winter K , et al . Factors associate death hospitalization due pandemic 2009 influenza A ( H1N1 ) infection California . JAMA 2009 ; 302 : 1896-902 . 4 . Jain S , Kamimoto L , Bramley AM , et al . Hospitalized patient 2009 H1N1 influenza United States , April-June 2009 . N Engl J Med 2009 ; 361:1935-44 . 5 . Chen H , Cheung CL , Tai H , et al . Oseltamivir-resistant influenza A pandemic ( H1N1 ) 2009 virus , Hong Kong , China . Emerg Infect Dis 2009 ; 15:1970-2 . 6 . Van Damme P , Oosterhuis-Kafeja F , Van der Wielen M , et al . Safety efficacy novel microneedle device dose spar intradermal influenza vaccination healthy adult . Vaccine 2009 ; 27:454-9 7 . Myers CA , Faix DJ , Blair PJ . Possible reduce effectiveness 2009 H1N1 component live , attenuate influenza vaccine . Clin Infect Dis . 2011 ; 15 ; 53:207-8.9 . 8 . Roukens R , Vossen AC , Boland GJ , et al . Intradermal hepatitis B vaccination non-responders topical application imiquimod ( Aldara ) . Vaccine 2010 ; 4288-4293 . 9 . Tyring S , Conant M , Marini M , Van Der Meijden W , Washenik K. Imiquimod , international update therapeutic us dermatology . Int J Dermatol 2002 ; 41 ( 11 ) :810-6 . 10 . Burns Jr RP , Ferbel B , Tomai M , Miller R , Gaspari AA . The imidazoquinolines , imiquimod R-848 , induce functional , phenotypic , maturation human epidermal Langerhans ' cell . Clin Immunol 2000 ; 94 ( 1 ) :13-23 . 11 . Suzuki H , Wang B , Shivji GM , Toto P , Amerio P , Tomai MA , et al . Imiquimod , topical immune response modifier , induces migration Langerhans cell . J Invest Dermatol 2000 ; 114 ( 1 ) :135-41 . 12 . Thomsen LL , Topley P , Daly MG , Brett SJ , Tite JP . Imiquimod resiquimod mouse model : adjuvant DNA vaccination particle-mediated immunotherapeutic delivery . Vaccine 2004 ; 22 ( 13-14 ) :1799-809 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>All adult patient age 21 chronic illness give write informed consent Subjects must available complete study comply study procedure . Willingness allow serum sample store beyond study period , potential additional future test good characterize immune response . Clinically significant immunerelated disease significant recent comorbidities Inability comprehend follow require study procedure History illness might interfere result study pose additional risk subject due participation study Have receive 2011/2012 TIV Have recent history ( document , confirm suspect ) flulike disease within week vaccination . Have know allergy egg component Study Vaccines ( include gelatin , formaldehyde , octoxinol , thimerosal , chicken protein ) , history anaphylaxis , serious vaccine reaction , excipients . Have positive urine serum pregnancy test within 24 hour prior vaccination , woman breastfeed . Female childbearing potential , use acceptable contraceptive method least 2 month prior study entry plan use acceptable birth control measure first 3 week vaccination . Have immunosuppression result underlie illness treatment , use anticancer chemotherapy radiation therapy ( cytotoxic ) within precede 36 month . Have active neoplastic disease history hematologic malignancy . Have longterm use glucocorticoid include oral , parenteral highdose inhaled steroid ( &gt; 800 mcg/day beclomethasone dipropionate equivalent ) within precede 6 month . ( Nasal topical steroid allow ) . Have history receive immunoglobulin blood product within 3 month prior vaccination study . Have know active human immunodeficiency virus ( HIV ) infection , acute hepatitis B C infection , autoimmune hepatitis relate cirrhosis Received experimental agent ( vaccine , drug , biologic , device , blood product , medication ) within 1 month prior vaccination study expect receive experimental agent study . Unwilling refuse participation another clinical study end study . History progressive severe neurological disorder Have receive licensed vaccine within 4 week inactivate licensed vaccine within 2 week prior vaccination study plan receipt vaccine within 21 day follow second vaccination ( exception unadjuvanted seasonal influenza vaccine allow 1 week prior 1 week study vaccination ) . Axillary temperature ≥ 38°C oral temperature ≥ 38.5°C within 3 day intend study vaccination Surgery plan study period Investigator 's opinion would interfere study visit schedule Have history alcohol drug abuse last 5 year . Have history GuillainBarré Syndrome . Have condition investigator believe may interfere successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>intradermal</keyword>
	<keyword>influenza</keyword>
	<keyword>vaccination</keyword>
</DOC>